The financials
Tempus AI, Inc. by the numbers
Tempus AI, Inc. (TEM) reported revenue of $382M in Q2 2026 (quarter ended June 30, 2026), up 22% from the same quarter a year earlier. That came with net income of $5.6M (1.5% of revenue). For the full year FY2025, revenue was $1.27B (+83% year on year) and net income −$245M. Its largest product in 2026-Q1 was Clinical Order at $239M, 69% of the disclosed total, just ahead of Insights Product at 20%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $382M | $315M | +22% |
| Operating income | −$76M | −$62M | n/a |
| Net income | $5.6M | −$43M | to a profit |
| Diluted EPS | $0.03 | −$0.25 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Clinical Order | $239M | 69% |
| Insights Product | $71M | 20% |
| Genomics Product | $22M | 6.3% |
| Trials Product | $9.9M | 2.8% |
| Next Product | $5.7M | 1.6% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $348.0M (-65%)
Next Product grew +111% year on yearTrials Product +2.1% year on year
Segment Latestquarter on quarteryear on year
- Clinical Order$239.3M$239.3MQoQ +1.7%year on year +32%+1.7%+32%
- Insights Product$71.3M$71.3MQoQ +3.3%year on year +44%+3.3%+44%
- Genomics Product$21.8M$21.8MQoQ -91%year on year +77%-91%+77%
- Trials Product$9.9M$9.9MQoQ +7.6%year on year +2.1%+7.6%+2.1%
- Next Product$5.7M$5.7MQoQ -year on year +111%-+111%
- Data And Other--QoQ -year on year ---
- Data And Services--QoQ -year on year ---
- Genomic--QoQ -year on year ---
Health Information Services
Ranks #12 of 14 by Smart Score